ICLR vs. INCY, MEDP, CRL, IQV, PHG, WST, ZBH, CAH, STE, and BNTX
Should you be buying ICON Public stock or one of its competitors? The main competitors of ICON Public include Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), IQVIA (IQV), Koninklijke Philips (PHG), West Pharmaceutical Services (WST), Zimmer Biomet (ZBH), Cardinal Health (CAH), STERIS (STE), and BioNTech (BNTX). These companies are all part of the "medical" sector.
Incyte (NASDAQ:INCY) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Incyte has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
Incyte received 615 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 73.58% of users gave Incyte an outperform vote while only 64.99% of users gave ICON Public an outperform vote.
97.0% of Incyte shares are owned by institutional investors. Comparatively, 95.6% of ICON Public shares are owned by institutional investors. 17.5% of Incyte shares are owned by company insiders. Comparatively, 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Incyte currently has a consensus price target of $73.69, indicating a potential upside of 29.82%. ICON Public has a consensus price target of $339.44, indicating a potential upside of 5.78%. Given ICON Public's higher possible upside, equities research analysts clearly believe Incyte is more favorable than ICON Public.
Incyte has a net margin of 19.78% compared to Incyte's net margin of 8.30%. ICON Public's return on equity of 12.83% beat Incyte's return on equity.
ICON Public has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
In the previous week, Incyte had 10 more articles in the media than ICON Public. MarketBeat recorded 15 mentions for Incyte and 5 mentions for ICON Public. Incyte's average media sentiment score of 0.59 beat ICON Public's score of 0.55 indicating that ICON Public is being referred to more favorably in the news media.
Summary
Incyte beats ICON Public on 9 of the 17 factors compared between the two stocks.
Get ICON Public News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ICON Public Competitors List
Related Companies and Tools
